Foothill Ventures — 2016 Investments
2 investments dated 2016 · listed companies and verified rows first · show all
NeuExcell develops gene therapies that convert the brain's glial cells into functional neurons using its ATN (Astrocytes-to-Neurons) NeuroD1 AAV-based platform to regenerate neurons at sites of injury.
BiotechDeep TechHealthtechLongevityMedical DevicesState College, US
Gong Chen(Co-founder | Chief Scientific Advisor | Board Chair)Yuchen Chen(Vice President | Board Director)
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Cureseq
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.